Abstract: The polyvinyl chloride-based fiber of the present invention is formed of a vinyl chloride-based resin composition obtained by blending, with respect to (a) 100 parts by weight of a vinyl chloride-based resin, (b) 0.1 parts by weight to 0.6 parts by weight of a hydrotalcite-based thermostabilizer, (c) 0.1 parts by weight to 0.5 parts by weight of ?-diketone, (d) 0.2 parts by weight to 0.5 parts by weight of a calcium soap and a zinc soap, (e) 0.7 parts by weight to 1.7 parts by weight of a lubricant, and (f) 0.5 parts by weight to 5 parts by weight of a plasticizer. Thereby, the present invention provides a polyvinyl chloride-based fiber that has an excellent touch feeling as a fiber for hair, excellent transparency and a vivid color tone, and can be obtained by stable melt spinning with less occurrence of filament breakage.

Abstract: The present invention provides a preparation for injection containing a lipid A analog and a process for preparing the same. A preparation for injection prepared by dissolving a lipid A analog or a pharmacologically acceptable salt thereof in an alkaline aqueous solution, at an elevated temperature if necessary, and then adding a buffer thereto, and a process for preparing the same.

Abstract: A preparation containing a cephalosporin medicament is disclosed. The preparation comprises a cephalosporin derivative represented by the following formula: ##STR1## namely, 7.beta.-{2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-fluoromethoxyiminoacetami do}-3-{(E)-3-(carbamoylmethylethylmethylammonio) -1-propen-1-yl}-3-cephem-4-carboxylate or a pharmaceutically acceptable salt thereof salt, lactose, citric acid or a sodium salt thereof, and arginine or a hydrochloride thereof; or the cephalosporin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof, lactose, citric acid or a sodium salt thereof, and sodium chloride.

Abstract: A medical composition which contains a tissue Plasminogen Activator (tPA) in combination with meglumine or a salt thereof.

Abstract: Disclosed herein are 7.beta.-[(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetamido]-3- (4-carbamoyl-1-quinuclidinio)methyl-3-cephem-4-carboxylate crystals comprising X-ray diffraction pattern possessing the characteristic diffraction intensity at the spacing d (unit: angstrom) shown in the following (i), (ii) or (iii):(i): 6.2, 5.1 and 5.0;(ii): 10.6, 5.3 and 5.1;(iii): 15.4, 5.0 and 4.6.A process for the preparation of the crystals is also disclosed.

Abstract: A composition containing a tissue Plasminogen Activator (tPA) which comprises a partial hydrolyzate of gelatin cross-linked to a diisocyanate as an essential ingredient; or alternatively a partial hydrolyzate of gelatin cross-linked to a diisocyanate and one or more of a basic amino acid or salt thereof. The composition enhances the solubility of the tPA in water, thereby making the tPA further available in the treatment of circulatory diseases caused by thrombi.

Abstract: A cephalosporin having the formula ##STR1## is stabilized in an injection solution with lactose and/or sodium chloride.